BACKGROUND AND TOPICS FOR DISCUSSION:

Populations are living longer than ever before, yet those extra years are not always lived in good health. Advances in integrative science, regenerative research, and AI-driven technologies are opening new frontiers to close the gap between lifespan and healthspan.

Founded by a chemist, L’Oréal Groupe has placed science at the heart of its mission for more than 115 years. With 4,000 researchers worldwide and more than 15 years of advanced longevity research reflected in 43 publications, the company is pioneering Longevity Integrative Science™. This work has decoded skin aging at the cellular, molecular, and tissue levels, created the Wheel of Longevity for Beauty, and developed the Longevity AI Cloud™, which maps more than 260 skin biomarkers. Partnerships with leading biotech companies, such as Timeline and Senisca, strengthen this research, while findings confirm that skin is not only a reflection of health but a predictive marker of systemic aging.

This panel will explore how science and culture converge to redefine aging—from targeting the root causes of biological decline to embracing new cultural narratives. Panelists will discuss how empowering individuals with predictive tools, regenerative innovations, and inclusive perspectives can unlock the full potential of longevity for patients and consumers alike.

BACKGROUND AND TOPICS FOR DISCUSSION:

From rare disease advocacy to large-scale translational science, patients are no longer just subjects of research, they are leaders reshaping how innovation happens. By creating registries, driving data collection, and directly funding studies, patient communities are accelerating discovery timelines that once spanned decades.

This panel highlights the paradigm shift toward patient-driven research. What does it mean when patients set priorities for discovery, design clinical trials, and partner with industry to validate new therapies? How do we operationalize this model at scale, ensuring that patients are not just included but empowered as co-creators of biomedical progress?

The discussion will examine rare diseases as a proving ground for this new approach, while exploring how lessons can be applied to broader global health challenges. Central questions include: what infrastructure and resources are needed to sustain patient-led innovation? How can industry, academia, and government adapt to a system where patients demand – not request – a seat at the table?

Ultimately, this panel confronts the systemic inequities that still constrain patient power. Ensuring that every patient community has a voice requires realignment of research priorities, new funding models, and legal frameworks that enable shared ownership of data and discoveries. The goal is not incremental change but a fundamental redesign of the R&D pipeline, one where patients are recognized as essential innovators driving a more equitable and effective future for global health.

Artificial intelligence thrives on data, and in healthcare, patient data is among the most valuable – and sensitive – resources available. With AI promising to accelerate discovery, improve diagnostics, and personalize care, the question is not whether patient data will fuel progress, but how it can be used responsibly, ethically, and equitably.

This panel examines the crossroads of innovation and responsibility. How can we unlock the power of AI to deliver better outcomes without sacrificing patient privacy and trust? What governance models, evidence standards, and safeguards are needed to ensure that “black box” algorithms serve patients rather than perpetuate bias or inequity?

The conversation will probe deeper systemic issues: how can patients themselves have greater agency in how their data is shared? What new partnerships between industry, regulators, and advocacy groups are required to define responsible AI use? And what would true transparency look like in systems that increasingly shape diagnosis, treatment, and access?

At stake is the balance between promise and peril. AI could revolutionize medicine, or it could deepen divides. This discussion will confront the choices that determine whether patient data becomes a tool for empowerment or exploitation.

BACKGROUND AND TOPICS FOR DISCUSSION: